For example, CK5 positivity has been described in 13.6 to 91% of bladder carcinomas [11, 16], 2.5 to 100% of breast carcinomas [17, 18], 59.5 to 100% of head and neck carcinoma [14, 19], 0 to 100% of lung carcinomas [20–25] and 74.8 to 93.8% of mesothelioma carcinomas [26–28]. Here, KRT5 is linked to breast carcinoma.